February 4, 2020

ORGANTRANS

European (EU) H2020 funded ORGANTRANS project is set to develop a disruptive solution that enables the 3D printing of tissue-engineered constructs. Coordinated by CSEM, eight consortium members will create a standardized and automated tissue preparation and maturation platform, which will provide patients with End-Stage Liver Disease (ESLD) an alternative to donor organ transplants.

Organtrans - new regenerative therapy
Press release

Related Press

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....

Customized skin tissue grafts

24 June 2021

CUTISS

CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has unveiled the world’s first automated machine to produce customized skin tissue...

Limula team

3 February 2023

Making personalized cancer therapies accessible to all

CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. ...